You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Summary of the patients’ therapies and follow-up results

From: Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

Pat. no. 177Lu- DOTATOC/ DOTATATE Therapeutic activity (GBq) Whole body residence time (h) Maximum voxel activity (kBq)# Lifetime in Tumor (h)§ Maximum absorbed voxel dose (Gy) Gy/GBq EBRT target dose (Gy) No. of fractions used for EBRT dose delivery Change of EBRT dose due to PRRT (Gy) Follow-up MR Follow–up symptoms
1 DOTATOC 7.0 39.3 71 72.4 4.0 0.57 60 30 0 No change Improvement of pituitary insufficiency,decreased vision unchanged
2 DOTATOC 7.3 19.1 277 29.7 6.6 0.90 48.6 27 −7 No change Retroorbital pressure fully resolved
3 DOTATOC 7.5 25.7 NA 60.1 4.0* 0.53 50 28 −4 No change Cranial nerve palsy fully resolved
4 DOTATOC 7.2 14.7 3 94.2 0.2 0.03 54 30 0 Complete remission Exophthalmus fully resolved
5 DOTATOC 7.6 17.1 191 44.0 6.7 0.88 54 30 0 No change Partial loss of vision, decresed general performance constant
6 DOTATOC 7.9 22.1 539 52.4 22.3 2.82 42 22 −11 No change Headache, hypesthesia improved
7 DOTATATE 7.9 27.2 557 68.2 30.7 3.89 60 30 0 No change Hemiparesis unchanged
8 DOTATATE 7.2 26.6 124 74.6 7.2 1.00 40 20 0 No change Paresis left leg unchanged
9 DOTATATE 7.3 32.3 305 69.6 16.6 2.27 54 30 0 Partial remission Epilepsy, tremor worsened, new hearing problems, resolved to pretherapeutic state after 2 months
10 DOTATATE 7.4 32.5 161 64.8 8.2 1.11 52 20 −6 No change Dizziness, ptosis constant
  1. # at 1 hour p.a. in 0.11 ³ voxel volume.
  2. § tumor residence time normalized to initial uptake.
  3. * no SPECT/CT data available, value deduced from PET uptake.